Natriuretic peptides in heart failure: where we are, where we are going

Correale, Michele; Totaro, Antonio; Greco, C

doi:10.1007/s11739-011-0600-0

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NT-proBNP values have previously shown their predictive ability in general patients with CHF. 3 , 4 One study tried to determine the effect of age on the short-term prognostic abilities of NT-proBNP values in elderly with CHF. 12 However, its study population was restricted to Caucasians with a mean age of 73.1 years, and thus its results might not be suitable for very older patients of other ethnicities.…”

Section: Discussionmentioning

confidence: 99%

“…N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recognized as a prognostically meaningful biomarker in patients with CHF. 3 , 4 However, few investigators have attempted to make use of NT-proBNP values to assess the risk of elderly with CHF. 5 The Seattle Heart Failure Score (SHFS) has been developed to determine the risk of dying, and has been validated as a useful tool in estimating CHF mortality in several data sets.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure

Fu¹,

Xie²,

Li³

et al. 2015

CIA

View full text Add to dashboard Cite

ObjectiveThis study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with patient characteristics, and screen for decisive factors of NT-proBNP in Chinese elderly with chronic heart failure (CHF).Patients and methodsThere were 306 patients (≥60 years) with CHF chosen as study subjects. Each one received an assessment of NT-proBNP on serum. The end point was all-cause mortality during a mean follow-up period of 471 days.ResultsSubjects had a median age of 85 (60–100) years, a median NT-proBNP of 1,743.4 pg/mL, and a median SHFS of 1.87. During the follow-up period, 104 deaths occurred. NT-proBNP was significantly related to mortality (odds ratio 1.603, 95% confidence interval 1.407–1.826; P<0.001) and the significance persisted after full adjustment (odds ratio 1.282, 95% confidence interval 1.103–1.489; P=0.001). Age, New York Heart Association class IV CHF, plasma albumin, and neutrophils/lymphocytes were also independent predictors for mortality (P<0.05 for all). NT-proBNP and the SHFS showed similar predictive capacities (0.736 versus 0.796, P=0.105). The addition of NT-proBNP to the SHFS (0.818 versus 0.796, P=0.168) generated marginal growth in the c-statistic. The model based on NT-proBNP consisting of all selected predictors in this study, including age, New York Heart Association class IV CHF, plasma albumin, neutrophils/lymphocytes, and NT-proBNP, had a moderately higher c-statistic compared with the SHFS (0.846 versus 0.796, P=0.066). NT-proBNP was bound with the SHFS (r=0.500, P<0.001). Characteristics regarding general condition, inflammation, and cardiac and renal function were the decisive factors of NT-proBNP (P<0.05 for all).ConclusionAs a comprehensive representation of the patient characteristics described earlier, NT-proBNP values provided significant prognostic power similar to the SHFS in Chinese elderly with CHF. A novel model based on NT-proBNP could offer help for risk stratification.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure

Fu¹,

Xie²,

Li³

et al. 2015

CIA

View full text Add to dashboard Cite

show abstract

“…We would like to specify some concepts regarding the letter of Correale et al [1]. There has been an important debate among experts concerning the importance of risk stratification and clinical management in heart failure.…”

mentioning

confidence: 99%

Natriuretic peptide in heart failure: where we are, where we are going. Answer to the letter

Palazzuoli

Nuti

2011

Intern Emerg Med

View full text Add to dashboard Cite

Natriuretic peptides in heart failure: where we are, where we are going

Cited by 2 publications

References 3 publications

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure

Natriuretic peptide in heart failure: where we are, where we are going. Answer to the letter

Contact Info

Product

Resources

About

Natriuretic peptides in heart failure: where we are, where we are going

Cited by 2 publications

References 3 publications

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart&nbsp;failure

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart&nbsp;failure

Natriuretic peptide in heart failure: where we are, where we are going. Answer to the letter

Contact Info

Product

Resources

About

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure